MediWound Ltd (F:M8W) — Market Cap & Net Worth
Market Cap & Net Worth: MediWound Ltd (M8W)
MediWound Ltd (F:M8W) has a market capitalization of $176.08 Million (€150.61 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #17026 globally and #1610 in its home market, demonstrating a -0.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MediWound Ltd's stock price €12.10 by its total outstanding shares 12852255 (12.85 Million). See how much does MediWound Ltd reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
MediWound Ltd Market Cap History: 2015 to 2026
MediWound Ltd's market capitalization history from 2015 to 2026. Data shows growth from $116.04 Million to $181.81 Million (5.56% CAGR).
MediWound Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MediWound Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.91x
MediWound Ltd's market cap is 13.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $70.14 Million | $1.56 Million | -$18.89 Million | 45.02x | N/A |
| 2017 | $54.53 Million | $2.50 Million | -$22.15 Million | 21.85x | N/A |
| 2018 | $50.94 Million | $3.40 Million | -$1.06 Million | 14.98x | N/A |
| 2019 | $39.07 Million | $31.79 Million | $4.96 Million | 1.23x | 7.88x |
| 2020 | $46.58 Million | $21.76 Million | -$9.20 Million | 2.14x | N/A |
| 2021 | $29.75 Million | $23.76 Million | -$13.55 Million | 1.25x | N/A |
| 2022 | $181.81 Million | $26.50 Million | -$19.60 Million | 6.86x | N/A |
| 2023 | $135.23 Million | $18.69 Million | -$6.72 Million | 7.24x | N/A |
| 2024 | $250.93 Million | $20.22 Million | -$30.22 Million | 12.41x | N/A |
| 2025 | $235.90 Million | $16.96 Million | -$23.88 Million | 13.91x | N/A |
Competitor Companies of M8W by Market Capitalization
Companies near MediWound Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to MediWound Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #569 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $478.71 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $760.66 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €728.00 |
| #569 | UCB SA | BR:UCB | $47.34 Billion | €223.30 |
MediWound Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, MediWound Ltd's market cap moved from $116.04 Million to $ 181.81 Million, with a yearly change of 5.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €181.81 Million | -22.93% |
| 2025 | €235.90 Million | -5.99% |
| 2024 | €250.93 Million | +85.56% |
| 2023 | €135.23 Million | -25.62% |
| 2022 | €181.81 Million | +511.11% |
| 2021 | €29.75 Million | -36.13% |
| 2020 | €46.58 Million | +19.23% |
| 2019 | €39.07 Million | -23.30% |
| 2018 | €50.94 Million | -6.59% |
| 2017 | €54.53 Million | -22.26% |
| 2016 | €70.14 Million | -39.56% |
| 2015 | €116.04 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of MediWound Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $176.08 Million USD |
| MoneyControl | $176.08 Million USD |
| MarketWatch | $176.08 Million USD |
| marketcap.company | $176.08 Million USD |
| Reuters | $176.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn cen… Read more